详细信息

Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database  ( SCI-EXPANDED收录)  

文献类型:期刊文献

英文题名:Drug-Related epileptic seizures and Age-Specific Differences: A Real-World study based on the FAERS database

作者:Wang, Zian[1];Mei, Hao[1];Song, Bangguo[1];Shi, Zhenggang[1]

第一作者:王铮;王珍

通信作者:Shi, ZG[1]

机构:[1]Gansu Univ Chinese Med, Sch Clin Chinese Med, Lanzhou, Peoples R China

第一机构:甘肃中医药大学

通信机构:[1]corresponding author), Gansu Univ Chinese Med, Lanzhou, Peoples R China.|[10735]甘肃中医药大学;

年份:2025

卷号:171

外文期刊名:EPILEPSY & BEHAVIOR

收录:;Scopus(收录号:2-s2.0-105012104230);WOS:【SCI-EXPANDED(收录号:WOS:001544989900001)】;

基金:This research was supported by the natural science foundation of China (project approval No.: 82460951).

语种:英文

外文关键词:Drug-related seizures; Adverse events; Faers database; Age difference; Signal detection; Induced time analysis

摘要:Background: Epileptic seizures are a serious neurological event that can be triggered by various medications, posing significant threats to patient safety and treatment compliance. With the increasing use of neurotoxic drugs such as antidepressants, antipsychotics, anti-infectives, and anticancer agents, drug-related epileptic seizures (DRES) have become an emerging concern in clinical pharmacovigilance. Despite growing awareness, limited real-world data exists on the age-specific risk patterns and onset timing of DRES. Objective: This study aimed to investigate the incidence trends, high-risk drugs, age-specific differences, and timeto-onset profiles of drug-related epileptic seizures using the FDA Adverse Event Reporting System (FAERS) from 2004 to 2024. Methods: A retrospective pharmacovigilance analysis was conducted using standardized MedDRA terms and RxNorm drug names. Disproportionality analysis via Reporting Odds Ratio (ROR) was applied to detect significant seizure-related safety signals. Subgroup analyses by age and time-to-onset distributions were performed, including Weibull survival modeling. Results: A total of 29,389 seizure-related adverse events were identified, with a marked increase in reports after 2011. The 15-44 age group accounted for the highest proportion (34.2 %). Bupropion (ROR: 5.62; 95 % CI: 5.21-6.07), Tramadol (ROR: 4.48; 95 % CI: 4.12-4.88), and Interferon beta-1a (ROR: 4.16; 95 % CI: 3.81-4.54) demonstrated consistently elevated seizure risk across all age groups. Age-specific signals included Methotrexate in children (0-14 years; ROR: 12.45; 95 % CI: 8.97-17.28) and Tranexamic Acid in the elderly (>60 years; ROR: 9.32; 95 % CI: 6.81-12.75). Eleven drugs not labeled for seizure risk in FDA documents, such as Meropenem and Indapamide, emerged as novel safety signals. Time-to-onset analysis showed that most drug-related seizure events occurred within 30 days of initiation, and Weibull modeling confirmed an early-failure time pattern across all age groups. Conclusion: This study provides real-world evidence on the epidemiological characteristics, age-related drug risk heterogeneity, and early-onset patterns of DRES. It highlights the need for individualized pharmacovigilance and regulatory updates to address under-recognized neurotoxic risks, particularly in vulnerable age groups. These findings contribute critical insights into safer prescribing practices and improved post-marketing surveillance.

参考文献:

正在载入数据...

版权所有©甘肃中医药大学 重庆维普资讯有限公司 渝B2-20050021-8 
渝公网安备 50019002500408号 违法和不良信息举报中心